



Published in final edited form as:

Tob Control. 2018 November ; 27(Suppl 1): s39–s40. doi:10.1136/tobaccocontrol-2018-054320.

Possible Hepatotoxicity of IQOS

Lauren Chun, BA¹, Farzad Moazed, MD¹, Michael Matthay, MD^{1,2,3}, Carolyn Calfee, MD MAS^{1,2,3}, and Jeffrey Gotts, MD PhD¹

¹Department of Medicine, UCSF, San Francisco, California, USA.

²Cardiovascular Research Institute, UCSF, San Francisco, California.

³Department of Anesthesia, UCSF, San Francisco, California.

On January 25, 2018, the FDA Tobacco Scientific Advisory Committee unanimously voted (with one abstention) that Phillip Morris International (PMI) could not claim their heated tobacco product (HTP) IQOS would reduce the risk of tobacco-related diseases. Regardless, IQOS is already available in over 30 countries, and thus merits scrutiny from the scientific and medical communities. The pre-clinical and clinical data PMI submitted to FDA indicate that IQOS exposure may be associated with unexpected liver toxicity. We reviewed pre-clinical studies conducted by PMI scientists¹ and clinical studies of 5 and 90 days of exposure to IQOS and IQOS menthol^{2–5} included in PMI's Modified Risk Tobacco Product application submitted to the US Food and Drug Administration.

Wong and colleagues¹ exposed 92 male and 92 female Sprague Dawley rats to up to 90 days of mainstream aerosol from IQOS, mainstream smoke from 3R4F research cigarettes, or room air (sham). After 90 days of exposure, liver weights and blood levels of alanine aminotransferase (ALT) were measured. ALT is an enzyme released into the blood by hepatocytes during hepatocellular injury⁶ and liver weight is a sensitive measure of hepatocellular hypertrophy.⁷ After 90 days, ALT levels and liver weights were significantly higher with IQOS than with conventional cigarettes in female animals (Table 1). Hepatocellular vacuolization, a sign of acute liver injury,⁷ was significantly increased in IQOS-exposed female rats, an effect not seen in cigarette-exposed animals (Table 1).

The human clinical data PMI submitted to FDA provide further cause for concern. Increased plasma bilirubin may signify cholestatic liver injury with impaired hepatic bile flow, accelerated red blood cell destruction, or decreased bilirubin metabolism.⁷ Following five days of exposure to IQOS, conventional cigarettes, or smoking abstinence, plasma bilirubin was elevated in 8.8% of IQOS subjects compared to 0% of cigarette smokers and 2.6% in abstainers.² In another 5-day study, the mean increase in ALT was higher with IQOS than with conventional cigarettes or smoking abstinence (4.5, 2.9, and 1.6 IU/L, respectively).³ In a 90-day study of exposure to mentholated IQOS, mentholated cigarettes or smoking abstinence, the only subject experiencing a Grade 2 (moderate) increase in ALT was in the IQOS group.⁴ In another study the rate of Grade 1 (mild) increases in ALT after 60 days of

exposure was highest with IQOS at 6.3% compared with 0% for conventional cigarettes and 2.6% with smoking abstinence.⁵

Hepatotoxicity constitutes a broad spectrum of injuries to the liver, with consequences ranging from asymptomatic lab abnormalities to hepatic failure and death.^{6,7} Notably, there is some evidence that smoking cessation may be associated with a small increase in the unconjugated fraction of bilirubin over the next 1–4 weeks, averaging 0.06 mg/dl.⁸ However, in the five day exposure study cited above, the rate of elevated bilirubin (>1.0 mg/dl) in IQOS users was over three times higher than that observed with smoking abstinence (8.8% vs. 2.6%), and the mean increase above baseline was 0.05 mg/dl with IQOS compared to –0.07 mg/dl with smoking abstinence.² We can find no evidence in the literature that smoking cessation is associated with an increase in ALT.

Taken together, PMI's pre-clinical and clinical data constitute a concerning pattern of possible hepatotoxicity, especially considering the short period of exposure. These findings indicate IQOS may have unexpected organ toxicity that has not been associated with cigarettes. Although IQOS exposes users to lower levels of many toxins than conventional cigarettes, it exposes users to higher levels of other toxins.⁹ Given the potential for synergistic hepatotoxicity with other medications (e.g., acetaminophen), alcohol,^{10,11} and herbal supplements, the public health community should focus intense scrutiny on possible liver injury in users of IQOS and other HTPs. A broader implication of this finding is that health assessments of IQOS and other non-cigarette tobacco products should consider possible toxicities not associated with conventional cigarettes.

REFERENCES

1. Wong ET, Kogel U, Veljkovic E, et al. Evaluation of the Tobacco Heating System 2.2. Part 4: 90-day OECD 413 rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects compared with cigarette smoke. *Regul Toxicol Pharmacol* 2016;81 Suppl 2:S59–S81. doi: 10.1016/j.yrtph.2016.10.015 [PubMed: 27793746]
2. Jarus-Dziedzic K A randomized, controlled, open-label, 3-arm parallel group, single-center study to demonstrate reductions in exposure to selected smoke constituents in smoking, healthy subjects switching to the Tobacco Heating System 2.2 (THS 2.2) or smoking abstinence, compared to continuing to use conventional cigarettes, for 5 days in confinement. In: PMP SA, ed. *ClinicalTrials.gov*: PMI Research & Development, 2013.
3. Miura H A randomized, controlled, open-label, 3-arm parallel group, single-center study to demonstrate reductions in exposure to selected smoke constituents in smoking, healthy subjects switching from conventional cigarettes to the Tobacco Heating System 2.2 (THS 2.2) or smoking abstinence, compared to smokers continuing to use conventional cigarettes for 5 days in confinement. In: PMP SA, ed. *ClinicalTrials.gov*: PMI Research & Development, 2013.
4. Oki M A randomized, controlled, open-label, 3-arm parallel group, multi-center study to demonstrate reductions in exposure to selected smoke constituents in healthy smokers switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or observing smoking abstinence, compared to continuing to use menthol conventional cigarettes, for 5 days in confinement and prolonged by 85 days in an ambulatory society. In: PMP SA, ed. *ClinicalTrials.gov*: PMI Research & Development, 2014.
5. Lewis W, Farmer FF. A randomized, controlled, open-label, 3-arm parallel group, multi-center study to demonstrate reductions in exposure to selected smoke constituents in apparently healthy smokers switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or observing smoking abstinence, compared to continuing to use menthol conventional cigarettes, for 5 days in

confinement and prolonged by 86 days in an ambulatory setting. In: PMP SA, ed. ClinicalTrials.gov: PMI Research & Development, 2014.

6. Alempijevic T, Zec S, Milosavljevic T. Drug-induced liver injury: Do we know everything? *World J Hepatol* 2017;9(10):491–502. doi: 10.4254/wjh.v9.i10.491 [PubMed: 28443154]
7. Hall AP, Elcombe CR, Foster JR, et al. Liver hypertrophy: A review of adaptive (adverse and non-adverse) changes—Conclusions from the 3rd international ESTP expert workshop. *Toxicol Pathology* 2012; 40: 971–994. doi: 10.1177/0192623312448935
8. O'Malley SO, Wu R, Mayne ST, Jatlow PI. Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. *Nic Tob Res* 2014; 16(8): 1145–9. doi: 10.1093/ntr/ntu067
9. St Helen G, Jacob P, Nardone N, et al. IQOS is Not A Reduced Exposure Product. *Tobacco Control* 2018 (SUBMITTED MANUSCRIPT)
10. Drobles DJ. Cue reactivity in alcohol and tobacco dependence. *Alcohol Clin Exp Res* 2002;26(12): 1928–9. doi: 10.1097/01.ALC.0000040983.23182.3A [PubMed: 12500123]
11. Batel P, Pessione F, Maitre C, et al. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. *Addiction* 1995;90(7):977–80. [PubMed: 7663320]

Table 1:

Liver parameters in Sprague Dawley rats after 90 days of exposure.

	Female			Male		
	Sham	IQOS	3R4F	Sham	IQOS	3R4F
ALT Levels (IU/l)	51.0±4.4	73.0±3.2 ^{**} ^	54.0±2.6	57.0±6.5	75.0±6.7 [*]	68.0±5.8
Liver Weight^{&}	339.6±6.6	442.6±10.2 ^{***} ^	386.7±15.1 [*]	329.3±5.1	381.7±13.2 ^{**}	373.0±7.9 ^{***}
Hepatocellular Vacuolization	0.7±0.4	1.5±0.2 [*]	1.2±0.3	1.4±0.3	0.8±0.4	1.8±0.8

Data are from reference 1 and are presented as mean ± S.E.M.

^{*} p < 0.05 relative to Sham;^{**} p < 0.01 relative to Sham;^{***} p < 0.001 relative to Sham;[^] p < 0.01 relative to 3R4F;[&] normalized to body weight and reported as ×10⁻⁴